Blog

Compound Cloud Featured in Latest UK Life Science Industries

BioAscent's Compound Cloud was featured in the latest edition of UK Life Sciences Industry. The full page article outlines Compound Cloud's offerings and describes the growth in online screening compound sales since it was launched a little over a year...

EPAC1 Partial Agonist Identified From Compound Cloud Custom Library

A collaborative screening project involving three Scottish Universities has identified a partial agonist for the cyclic AMP receptor EPAC1 from a Compound Cloud custom library. The research involved academics from Heriot-Watt, Dundee and Glasgow universities, with the results published online by...

Fragment-Based Drug Discovery

With the second ever FDA approval of a fragment derived drug in April, the potential of fragment-based drug design (FBDD) was discussed in September's Nature Reviews Drug Discovery. The article which can be found here addresses the strengths of fragment...

Compound Cloud in Drug Discovery Today

Compound Cloud feature in this month's Drug Discovery Today paper "The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma". The authors describe their creation of a custom screening library from Compound Cloud to run pilot screens...